Amgen Inc. (NASDAQ:AMGN) Given Consensus Rating of "Hold" by Analysts

Key Points

• Amgen has a consensus analyst rating of “Hold”, based on coverage from 31 research firms. The average 12-month price target is about $355.19, with analysts split between sell, hold, buy, and strong buy views.
• The company beat quarterly earnings expectations, reporting EPS of $5.15 versus the $4.77 estimate, while revenue came in slightly above forecasts at $8.62 billion. Amgen also lifted its FY 2026 EPS guidance to 21.7–23.1.
• Amgen announced a quarterly dividend of $2.52 per share, implying an annualized payout of $10.08 and a 3.0% yield. Institutional ownership remains high, with hedge funds and other investors holding 76.5% of the stock.

Amgen Inc. (NASDAQ:AMGN - Get Free Report) has been given a consensus rating of "Hold" by the thirty-one research firms that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, fourteen have assigned a hold recommendation, thirteen have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $355.1923.

A number of equities analysts have issued reports on the company. Erste Group Bank reiterated a "hold" rating on shares of Amgen in a report on Tuesday, May 5th. UBS Group increased their price objective on Amgen from $390.00 to $400.00 and gave the stock a "buy" rating in a report on Monday, April 13th. The Goldman Sachs Group increased their price objective on Amgen from $415.00 to $425.00 and gave the stock a "buy" rating in a report on Friday, May 1st. Jefferies Financial Group assumed coverage on Amgen in a report on Tuesday, March 10th. They issued a "hold" rating and a $350.00 price objective for the company. Finally, Royal Bank Of Canada increased their price objective on Amgen from $360.00 to $370.00 and gave the stock an "outperform" rating in a report on Tuesday, April 7th.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company's stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.85% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Amgen by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company's stock valued at $17,949,296,000 after buying an additional 961,975 shares in the last quarter. State Street Corp lifted its position in shares of Amgen by 4.4% during the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company's stock valued at $10,012,872,000 after buying an additional 1,287,310 shares in the last quarter. Capital World Investors lifted its position in shares of Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company's stock valued at $7,560,249,000 after buying an additional 4,302,237 shares in the last quarter. Capital International Investors lifted its position in shares of Amgen by 1.5% during the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company's stock valued at $5,414,296,000 after buying an additional 282,219 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company's stock valued at $4,665,822,000 after buying an additional 1,035,779 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Up 0.2%

Shares of AMGN opened at $331.57 on Thursday. The firm has a market cap of $178.94 billion, a P/E ratio of 23.07, a P/E/G ratio of 3.32 and a beta of 0.44. The stock has a 50 day simple moving average of $346.62 and a two-hundred day simple moving average of $344.14. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. Amgen has a 1 year low of $267.83 and a 1 year high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts' consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business's quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts forecast that Amgen will post 22.37 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. Amgen's dividend payout ratio (DPR) is presently 70.15%.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.